|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root
of resistance. Cancer Lett. 372:147–156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leon G, MacDonagh L, Finn SP, Cuffe S and
Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting
cell surface markers and signaling pathways. Pharmacol Ther.
158:71–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Signore M, Ricci-Vitiani L and De Maria R:
Targeting apoptosis pathways in cancer stem cells. Cancer Lett.
332:374–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xia Y, Zhang YL, Yu C, Chang T and Fan HY:
YAP/TEAD co-activator regulated pluripotency and chemoresistance in
ovarian cancer initiated cells. PLoS One. 9:e1095752014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan Y, Li D, Li H, Wang L, Tian G and
Dong Y: YAP overexpression promotes the epithelial-mesenchymal
transition and chemoresistance in pancreatic cancer cells. Mol Med
Rep. 13:237–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang
LL, Gai RH, Zhu DF, Yang B, Zhu H and He QJ: Nuclear translocation
and activation of YAP by hypoxia contributes to the chemoresistance
of SN38 in hepatocellular carcinoma cells. Oncotarget. 7:6933–6947.
2016.PubMed/NCBI
|
|
9
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujimoto D, Ueda Y, Hirono Y, Goi T and
Yamaguchi A: PAR1 participates in the ability of multidrug
resistance and tumorigenesis by controlling Hippo-YAP pathway.
Oncotarget. 6:34788–34799. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ,
Bian XW, Yu SC and Qian GS: Mitochondrial and energy
metabolism-related properties as novel indicators of lung cancer
stem cells. Int J Cancer. 129:820–831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH,
Chen SS, Song J and Ye XQ: Enhanced expression of stem cell markers
and drug resistance in sphere-forming non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:6287–6300. 2015.PubMed/NCBI
|
|
13
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan EH, Nousiainen M, Chalamalasetty RB,
Schäfer A, Nigg EA and Silljé HH: The Ste20-like kinase Mst2
activates the human large tumor suppressor kinase Lats1. Oncogene.
24:2076–2086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Praskova M, Xia F and Avruch J:
MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell
proliferation. Curr Biol. 18:311–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and
Qiu X: Overexpression of yes-associated protein contributes to
progression and poor prognosis of non-small-cell lung cancer.
Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Diep CH, Zucker KM, Hostetter G, Watanabe
A, Hu C, Munoz RM, Von Hoff DD and Han H: Down-regulation of Yes
associated protein 1 expression reduces cell proliferation and
clonogenicity of pancreatic cancer cells. PLoS One. 7:e327832012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun
ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al: Genetic landscape of
esophageal squamous cell carcinoma. Nat Genet. 46:1097–1102. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu G, Yu FX, Kim YC, Meng Z, Naipauer J,
Looney DJ, Liu X, Gutkind JS, Mesri EA and Guan KL: Kaposi
sarcoma-associated herpesvirus promotes tumorigenesis by modulating
the Hippo pathway. Oncogene. 34:3536–3546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao JJ, Zhao XM, Wang DL, Chen KH, Sheng
X, Li WB, Li MC, Liu WJ and He J: YAP is overexpressed in clear
cell renal cell carcinoma and its knockdown reduces cell
proliferation and induces cell cycle arrest and apoptosis. Oncol
Rep. 32:1594–1600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang W, Nandakumar N, Shi Y, Manzano M,
Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et
al: Downstream of mutant KRAS, the transcription regulator YAP is
essential for neoplastic progression to pancreatic ductal
adenocarcinoma. Sci Signal. 7:ra422014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lau AN, Curtis SJ, Fillmore CM, Rowbotham
SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW,
Walton ZE, et al: Tumor-propagating cells and Yap/Taz activity
contribute to lung tumor progression and metastasis. EMBO J.
33:468–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka I, Osada H, Fujii M, Fukatsu A,
Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T and
Sekido Y: LIM-domain protein AJUBA suppresses malignant
mesothelioma cell proliferation via Hippo signaling cascade.
Oncogene. 34:73–83. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song S, Ajani JA, Honjo S, Maru DM, Chen
Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al:
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal
cancer cells with stem-like properties. Cancer Res. 74:4170–4182.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 regulates OCT4
activity and SOX2 expression to facilitate self-renewal and
vascular mimicry of stem-like cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huo X, Zhang Q, Liu AM, Tang C, Gong Y,
Bian J, Luk JM, Xu Z and Chen J: Overexpression of Yes-associated
protein confers doxorubicin resistance in hepatocellullar
carcinoma. Oncol Rep. 29:840–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
